A naukri.com initiative
Physicsworld
1M
103
Image Credit: Physicsworld
Hybrid irradiation could facilitate clinical translation of FLASH radiotherapy
- FLASH radiotherapy delivers radiation at high dose rates to tumours, with reduced injury to healthy tissues.
- Preclinical studies show that FLASH radiotherapy has potential to produce better anti-tumour effects in some types of cancer.
- One challenge facing FLASH radiotherapy is the limitation of existing electron beams.
- Researchers at Lausanne University Hospital & the University of Lausanne demonstrated that a hybrid ultrahigh-dose rate (UHDR) electron & conventional dose rate (CDR) photon radiotherapy could significantly overcome the deep-seated tumour treatment challenge.
- The team's proof-of-concept study showed that a hybrid approach combining both UHDR and CDR radiotherapy for glioblastoma, pancreatic cancer and localized prostate cancer was equivalent to conventional radiotherapy.
- This hybrid approach is achievable through dual-use clinically approved linear accelerators (linac).
- The hybrid study delivered the majority of the prescribed dose per treatment fraction at UHDR and without delivery pauses.
- The researchers also estimated the potential FLASH sparing effect achievable with their hybrid technique.
- The team is currently working on further enhancing plan quality, flexibility, and UHDR proportion of the delivered dose using the hybrid treatment approach.
- Additional research is ongoing to quantify its biological benefits and explore its technical realization.
Read Full Article
6 Likes
For uninterrupted reading, download the app